As the U.S. stock market faces a downturn, with technology sectors slumping and gold reaching record highs, investors are on edge about potential interest rate cuts and trade policy uncertainties. In such volatile times, penny stocks—often associated with smaller or newer companies—can still present intriguing opportunities for those seeking affordability combined with growth potential. Despite their vintage name, these stocks can offer surprising value when backed by strong financials, as we explore three noteworthy examples in this article.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.12 | $441.47M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.76 | $622.06M | ✅ 4 ⚠️ 0 View Analysis > |
| VTEX (VTEX) | $4.03 | $742.41M | ✅ 3 ⚠️ 1 View Analysis > |
| WM Technology (MAPS) | $1.14 | $212.07M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.83 | $23.5M | ✅ 4 ⚠️ 2 View Analysis > |
| Table Trac (TBTC) | $4.892 | $22.5M | ✅ 2 ⚠️ 2 View Analysis > |
| Riverview Bancorp (RVSB) | $4.93 | $106M | ✅ 2 ⚠️ 1 View Analysis > |
| BAB (BABB) | $0.9595 | $6.9M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $4.20 | $89.5M | ✅ 3 ⚠️ 3 View Analysis > |
| TETRA Technologies (TTI) | $4.76 | $626.41M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 375 stocks from our US Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Metalpha Technology Holding (MATH)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Metalpha Technology Holding Limited, with a market cap of $114.92 million, operates in Hong Kong offering wealth management services through its subsidiaries.
Operations: The company generates revenue of $44.57 million from trading proprietary digital assets and derivative contracts.
Market Cap: $114.92M
Metalpha Technology Holding Limited, with a market cap of US$114.92 million, has shown significant financial improvement, reporting a net income of US$15.89 million for the fiscal year ending March 31, 2025. The company operates debt-free and boasts strong short-term asset coverage over liabilities. Its recent strategic partnership with AMINA Bank AG aims to enhance its digital asset solutions amid growing institutional demand for crypto exposure. Despite high volatility in share price over the past three months and an inexperienced management team averaging less than one year in tenure, Metalpha's return on equity is outstanding at 43.5%.
- Unlock comprehensive insights into our analysis of Metalpha Technology Holding stock in this financial health report.
- Gain insights into Metalpha Technology Holding's past trends and performance with our report on the company's historical track record.
AC Immune (ACIU)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines as well as therapeutic and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $201.84 million.
Operations: The company generates revenue of CHF 28.92 million from its segment focused on the discovery and development of therapeutic and diagnostic products.
Market Cap: $201.84M
AC Immune SA, with a market cap of $201.84 million, remains unprofitable but has shown some financial resilience by reducing its losses over the past five years at a rate of 3.5% annually. Despite being debt-free and having short-term assets exceeding both short- and long-term liabilities, the company faces high share price volatility and negative return on equity. Recent earnings reports indicate revenue growth to CHF 1.31 million for Q2 2025, yet net losses persist at CHF 21.19 million for the quarter. Leadership changes include Dr Günther Staffler's promotion to Executive Vice President, Development, enhancing focus on immunotherapy programs.
- Click here to discover the nuances of AC Immune with our detailed analytical financial health report.
- Review our growth performance report to gain insights into AC Immune's future.
BBX Capital (BBXI.A)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: BBX Capital, Inc. is a diversified holding company based in Florida with a market capitalization of $52.61 million.
Operations: The company's revenue is primarily derived from its segments, including Renin with $90.97 million, Altman at $80.18 million, and BBX Sweet Holdings contributing $128.78 million.
Market Cap: $52.61M
BBX Capital, Inc., with a market cap of US$52.61 million, faces challenges as it remains unprofitable and has seen its earnings decline by 22.2% annually over the past five years. Despite this, the company maintains a strong balance sheet with short-term assets of US$201.5 million exceeding both short- and long-term liabilities. BBX Capital's board and management teams are experienced, each averaging five years of tenure. Although its debt-to-equity ratio has slightly increased to 28.8%, the company holds more cash than total debt, ensuring a cash runway for over a year if current trends persist.
- Get an in-depth perspective on BBX Capital's performance by reading our balance sheet health report here.
- Assess BBX Capital's previous results with our detailed historical performance reports.
Make It Happen
- Gain an insight into the universe of 375 US Penny Stocks by clicking here.
- Ready To Venture Into Other Investment Styles? This technology could replace computers: discover the 23 stocks are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if BBX Capital might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com